A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bio Techne Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 35,100 shares of TECH stock, worth $2.41 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
35,100
Previous 43,500 19.31%
Holding current value
$2.41 Million
Previous $3.12 Million 10.01%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$70.96 - $82.35 $67.2 Million - $77.9 Million
946,543 Added 366.96%
1,204,484 $96.3 Million
Q2 2024

Aug 14, 2024

BUY
$62.12 - $84.15 $9.75 Million - $13.2 Million
156,876 Added 155.22%
257,941 $18.5 Million
Q1 2024

May 15, 2024

BUY
$65.98 - $77.09 $6.67 Million - $7.79 Million
101,065 New
101,065 $7.11 Million
Q3 2023

Nov 14, 2023

BUY
$67.52 - $89.42 $13.9 Million - $18.5 Million
206,426 Added 194.55%
312,533 $21.3 Million
Q2 2023

Aug 14, 2023

SELL
$73.76 - $85.98 $32.9 Million - $38.4 Million
-446,457 Reduced 80.8%
106,107 $8.66 Million
Q1 2023

May 15, 2023

BUY
$71.62 - $86.62 $36.6 Million - $44.2 Million
510,677 Added 1219.18%
552,564 $41 Million
Q4 2022

Feb 14, 2023

SELL
$80.67 - $352.29 $6.09 Million - $26.6 Million
-75,545 Reduced 64.33%
41,887 $3.47 Million
Q3 2022

Nov 14, 2022

BUY
$282.54 - $391.85 $31.1 Million - $43.1 Million
109,981 Added 1476.06%
117,432 $33.4 Million
Q2 2022

Aug 15, 2022

SELL
$322.67 - $449.65 $13.8 Million - $19.3 Million
-42,887 Reduced 85.2%
7,451 $2.58 Million
Q1 2022

May 16, 2022

BUY
$353.85 - $487.79 $17.3 Million - $23.9 Million
48,990 Added 3634.27%
50,338 $21.8 Million
Q4 2021

Feb 14, 2022

SELL
$456.15 - $525.06 $9.58 Million - $11 Million
-20,997 Reduced 93.97%
1,348 $697,000
Q3 2021

Nov 15, 2021

BUY
$444.87 - $538.88 $1.11 Million - $1.34 Million
2,485 Added 12.51%
22,345 $10.8 Million
Q2 2021

Aug 16, 2021

BUY
$387.35 - $450.26 $7.29 Million - $8.48 Million
18,833 Added 1833.79%
19,860 $8.94 Million
Q1 2021

May 17, 2021

SELL
$314.62 - $411.0 $5.51 Million - $7.2 Million
-17,509 Reduced 94.46%
1,027 $392,000
Q4 2020

Feb 16, 2021

BUY
$246.9 - $321.87 $2.11 Million - $2.74 Million
8,526 Added 85.17%
18,536 $5.89 Million
Q3 2020

Nov 16, 2020

SELL
$232.22 - $282.96 $10.8 Million - $13.1 Million
-46,436 Reduced 82.27%
10,010 $2.48 Million
Q2 2020

Aug 14, 2020

BUY
$185.43 - $279.56 $8.81 Million - $13.3 Million
47,503 Added 531.18%
56,446 $14.9 Million
Q1 2020

May 15, 2020

SELL
$161.17 - $221.51 $8.15 Million - $11.2 Million
-50,574 Reduced 84.97%
8,943 $1.7 Million
Q4 2019

Feb 14, 2020

BUY
$189.68 - $222.09 $9.88 Million - $11.6 Million
52,075 Added 699.74%
59,517 $13.1 Million
Q3 2019

Nov 14, 2019

SELL
$183.56 - $216.72 $13.3 Million - $15.7 Million
-72,403 Reduced 90.68%
7,442 $1.46 Million
Q2 2019

Aug 14, 2019

SELL
$188.72 - $215.43 $6.47 Million - $7.39 Million
-34,305 Reduced 30.05%
79,845 $16.6 Million
Q1 2019

May 15, 2019

BUY
$136.09 - $200.44 $10 Million - $14.8 Million
73,834 Added 183.14%
114,150 $0
Q4 2018

Feb 14, 2019

BUY
$132.75 - $203.8 $142,440 - $218,677
1,073 Added 2.73%
40,316 $5.83 Million
Q3 2018

Nov 13, 2018

SELL
$147.44 - $204.11 $1.86 Million - $2.57 Million
-12,598 Reduced 24.3%
39,243 $0
Q2 2018

Aug 10, 2018

SELL
$144.9 - $165.58 $2.6 Million - $2.97 Million
-17,950 Reduced 25.72%
51,841 $0
Q1 2018

May 11, 2018

SELL
$131.46 - $151.04 $45.6 Million - $52.4 Million
-346,945 Reduced 83.25%
69,791 $10.5 Million
Q4 2017

Feb 09, 2018

BUY
$121.17 - $134.75 $11.3 Million - $12.6 Million
93,175 Added 28.8%
416,736 $54 Million
Q3 2017

Nov 09, 2017

BUY
$113.59 - $123.78 $36.8 Million - $40.1 Million
323,561
323,561 $39.1 Million

Others Institutions Holding TECH

About BIO-TECHNE Corp


  • Ticker TECH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,222,600
  • Market Cap $2.7B
  • Description
  • Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures bi...
More about TECH
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.